The startup develops cancer-specific immunotherapy utilizing adoptive cell therapy to generate tumor-specific T-cells that trigger a polyclonal immune response against solid tumors. This approach aims to enhance treatment outcomes by targeting multiple tumor antigens, addressing the limitations of conventional cancer therapies.
Funding
$44.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Solid tumors often evade conventional cancer therapies due to their heterogeneous nature and ability to suppress the immune system. Current treatments may not effectively target all tumor cells, leading to recurrence and limited long-term survival for patients with advanced solid malignancies.
Solution
This startup is developing a cancer-specific immunotherapy platform based on adoptive cell therapy to generate tumor-specific T-cells. The approach aims to overcome tumor heterogeneity by engineering T-cells to recognize and target multiple tumor-associated antigens, triggering a polyclonal immune response. By targeting a diverse set of antigens, the therapy seeks to enhance the breadth and depth of the anti-tumor response, potentially leading to more durable remissions in patients with solid tumors. The engineered T-cells are designed to infiltrate the tumor microenvironment, overcome immunosuppressive mechanisms, and directly kill cancer cells.
Target Audience
The primary target audience includes patients with advanced solid tumors who have failed to respond to or have relapsed after standard-of-care therapies, as well as oncologists and hematologists specializing in cell-based immunotherapies.
Features
- Adoptive cell therapy approach utilizing patient-derived or allogeneic T-cells
- T-cells engineered to target multiple tumor-associated antigens
- Polyclonal T-cell response to address tumor heterogeneity
- Enhanced T-cell infiltration into the tumor microenvironment
- Overcoming immunosuppressive mechanisms within the tumor
- Direct killing of cancer cells by engineered T-cells